Circulating micro RNAs as biomarkers for diagnosis, prognosis and treatment response in cardiovascular disease
| miRNA | Biomarker value | Condition | Respective fold change vs controls | Ref |
| miR-22, −92b, −320a, −423–5 p | Diagnosis | Chronic heart failure | Up (1.4; 1.3; 1.2; 1.5) | 73 |
| miR-30c, −146a, −221,–375 | Diagnosis | Chronic heart failure | Down (0.6; 0.7; 0.4; 0.45) | 68 |
| miR-107,–139, −142–5 p | Diagnosis | Chronic heart failure | Down (0.3; 0.2; 0.52) | 75 |
| miR-193b-3p, −193b-5p, −183–3 p, −190a, −211–5 p, −494 | Diagnosis | Chronic heart failure | Down (0.4; 0.5; 0.4; 0.5; 0.45; 0.2) | 69 |
| miR-423–5 p | Diagnosis | Acute heart failure | Up (2.5) | 100 |
| miR-499 | Diagnosis | Acute heart failure | Up (100) | 101 |
| miR-106a-5p, −652–3 p, −18a-5p, −27a-3p, −199a-3p | Diagnosis | Acute heart failure | Down (<0.5 fold, for all) | 105 |
| miR-30b, −103, −142–3 p, −342–3 p | Diagnosis | Acute heart failure | Down (0.4; 0.6; 0.4; 0.5) | 70 |
| miR-30c, −146a | Diagnosis | HFpEF vs HFrEF | Down (0.8; 0.7) | 68 |
| miR-221,–328, −375 | Diagnosis | HFpEF vs HFrEF | Up (1.25; 1.7; 1.4) | 68 |
| miR-29a | Diagnosis | Cardiac fibrosis and hypertrophic cardiomyopathy | Up (3.1) | 102 |
| miR-18a-5p, −652–3 p | Prognosis | Heart failure, 180 day all cause mortality | Down (<0.5 fold, for all) | 105 |
| miR-126, −508–5 p | Prognosis | Cardiovascular death after 2 years | Up (1.33; 10.2) | 104 |
| miR-30d | Prognosis | Acute heart failure, 1 year all cause mortality | Down (0.33) | 106 |
| miR-26b-5p, −29a-3p, −92a-3p, 145–5 p, −30e-5p | Treatment response | 12 months after effective CRT | Up (15.2; 9; 14; 6; 8) | 107 |
| miR-1, −208a/208b, −499 | Treatment response | 3 months after LVAD | Down (0.1; 0.03; 0.014) | 111 |
| miR-1202 | Treatment response | 3 months after LVAD | Down (0.9) | 110 |
CRT, cardiac resynchronisation therapy; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVAD, left ventricular assist device.